Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Supernus Pharm
(NQ:
SUPN
)
34.07
-0.80 (-2.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
377,694
Open
34.69
Bid (Size)
33.36 (1)
Ask (Size)
34.79 (1)
Prev. Close
34.87
Today's Range
34.01 - 35.03
52wk Range
23.05 - 35.56
Shares Outstanding
53,145,884
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
Today 16:10 EDT
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
October 21, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
+22.86%
+22.86%
1 Month
+9.27%
+9.27%
3 Month
+14.25%
+14.25%
6 Month
+13.26%
+13.26%
1 Year
+42.85%
+42.85%
More News
Read More
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
October 17, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
October 10, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
September 24, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
September 19, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
September 11, 2024
Via
Benzinga
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
September 11, 2024
Via
Benzinga
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
September 11, 2024
Via
Benzinga
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
August 28, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
August 19, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Second Quarter 2024 Financial Results
August 06, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
For those who appreciate value investing, NASDAQ:SUPN is a compelling option with its solid fundamentals.
August 06, 2024
Via
Chartmill
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
August 01, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
July 23, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
July 19, 2024
Via
InvestorPlace
NASDAQ:SUPN is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
July 05, 2024
Via
Chartmill
Trading SMID Biotech Stocks In A Volatile Market
July 01, 2024
Via
Talk Markets
Investors should take notice of NASDAQ:SUPN—it offers a great deal for the fundamentals it presents.
June 14, 2024
Via
Chartmill
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
May 23, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
May 09, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024
May 08, 2024
Via
InvestorPlace
Supernus Announces First Quarter 2024 Financial Results
May 08, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
May 02, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.